• Home
  • Latest
  • Coins2Day 500
  • Finance
  • Tech
  • Leadership
  • Lifestyle
  • Rankings
  • Multimedia
Coronavirus

Malaria drug Trump touted as ‘game changer’ for coronavirus treatment fails in new study

By
Michelle Fay Cortez
Michelle Fay Cortez
and
Bloomberg
Bloomberg
Down Arrow Button Icon
By
Michelle Fay Cortez
Michelle Fay Cortez
and
Bloomberg
Bloomberg
Down Arrow Button Icon
May 7, 2020, 11:31 PM ET

A malaria drug that was touted by U.S. President Donald Trump and widely used as a potential treatment for patients with Covid-19 failed to help those with infections stay off ventilators or live longer, according to a study published in the New England Journal of Medicine.

Researchers at New York-Presbyterian Hospital and Columbia University Irving Medical Center in New York City evaluated 1,376 consecutive patients who showed up at the emergency room with symptoms of coronavirus, comparing the fate of those who received the medication, hydroxychloroquine, to those who didn’t. Nearly 60% of the patients were given the drug, typically within 48 hours, and they were more sick on average.

There were no significant differences between the groups in the number of patients who needed to be put on a ventilator or who died, even after taking into account the differences between them, the researchers said.

Additional study, including more scientifically rigorous trials that randomly assign patients to treatment groups, is needed to confirm the findings, they said.

The results shouldn’t be used to rule out either a potential benefit or harm from the drug, though they don’t support use of the medication outside of clinical trials, the researchers said. The medical center updated its clinical guidance to remove the suggestion that patients with Covid-19 should receive it.

When Trump began touting the drug as a “game changer” for Covid-19 in March, a frenzy ensued as hospitals, patients and doctors raced to secure supplies. The president has stopped talking about hydroxychloroquine as the tide has now turned against the drug, with regulators and scientists raising concerns about potentially serious side effects.

More coronavirus coverage from Coins2Day:

—The Rebuild Program: A project to help small businesses reopen amid a pandemic
—Real unemployment rate soars past 24.9%—and the U.S. Has now lost 33.5 million jobs
—McConnell focuses Senate on conservative judge appointments rather than coronavirus
—Photo essay: What life looks like in Europe as the continent starts to reopen
—Trump’s demand that China pay coronavirus reparations evokes an ugly history
—The coronavirus is driving a mental health crisis. Tech can help tackle it
—IBM thinks tech tested by astronauts could help us take care of isolated loved ones
—PODCAST: How Marc Benioff is helping out during the coronavirus pandemic
—WATCH: Coins2Day’s top 10 heroes of the coronavirus pandemic

Subscribe to How To Reopen, Coins2Day’s weekly newsletter on what it takes to reboot business in the midst of a pandemic

About the Authors
By Michelle Fay Cortez
See full bioRight Arrow Button Icon
By Bloomberg
See full bioRight Arrow Button Icon

Latest in International

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025

Most Popular

Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Finance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam
By Coins2Day Editors
October 20, 2025
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • Mpw
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms Of Use
  • Single Issues For Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work At Coins2Day
  • Diversity And Inclusion
  • Terms And Conditions
  • Site Map
  • Facebook icon
  • Twitter icon
  • LinkedIn icon
  • Instagram icon
  • Pinterest icon

Most Popular

placeholder alt text
Economy
'I just don't have a good feeling about this': Top economist Claudia Sahm says the economy quietly shifted and everyone's now looking at the wrong alarm
By Eleanor PringleJanuary 31, 2026
20 hours ago
placeholder alt text
Success
Alexis Ohanian walked out of the LSAT 20 minutes in, went to a Waffle House, and decided he was 'gonna invent a career.' He founded Reddit
By Preston ForeJanuary 31, 2026
12 hours ago
placeholder alt text
Success
Ryan Serhant starts work at 4:30 a.m.—he says most people don’t achieve their dreams because ‘what they really want is just to be lazy’
By Preston ForeJanuary 31, 2026
15 hours ago
placeholder alt text
Future of Work
Ford CEO has 5,000 open mechanic jobs with up to 6-figure salaries from the shortage of manually skilled workers: 'We are in trouble in our country'
By Marco Quiroz-GutierrezJanuary 31, 2026
12 hours ago
placeholder alt text
Economy
Right before Trump named Warsh to lead the Fed, Powell seemed to respond to some of his biggest complaints about the central bank
By Jason MaJanuary 30, 2026
1 day ago
placeholder alt text
AI
Top engineers at Anthropic, OpenAI say AI now writes 100% of their code—with big implications for the future of software development jobs
By Beatrice NolanJanuary 29, 2026
2 days ago

© 2026 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.

0